Ira Mellman/fiercebiotech.com
Apr 11, 2025, 09:33
Ira Mellman has joined PICI as President of Research
Parker Institute for Cancer Immunotherapy posted on X:
“Turning all cancers into curable diseases takes urgency, bold ideas and relentless drive. To advance that mission, we’re proud to share that Ira Mellman, PhD, has joined PICI as President of Research.
A leader in cancer immunology, Dr. Mellman helped shape therapies like Tecentriq, anti-TIGIT and personalized vaccines at Genentech. His research at Yale laid the groundwork for principles still guiding the field today.
At PICI, he’ll leverage his deep scientific expertise to support our network and help move the science faster, and further, toward cures.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023